AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24216113 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group (n = 107)
Number of subjects: 428
Study 24216113 — intervention group
Group type: EXPERIMENTAL
Intervention: All acupuncture groups
Number of subjects: 428
Study 21297128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-RT MRI parameters (T2 hyperintensity lesion volume, nonenhancing lesion volume)
Number of subjects: 64
Study 21297128 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-RT MRI parameters (normalized cerebral blood volumes, normalized peak height, normalized recirculation factors)
Number of subjects: 64
Study 21297128 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in MRI parameters from pre-RT to post-RT (nCBV, nPH, ADC)
Number of subjects: 64
Study 21297128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-RT nRF values
Number of subjects: 64
Study 21297128 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in nRF from pre-RT to post-RT
Number of subjects: 64
Study 21297128 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns of changes in ADC and anatomic volumes
Number of subjects: 64
Study 21297128 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in nCBV, nPH, and contrast-enhancing volume
Number of subjects: 64
Study 19133058 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 20
Study 19133058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17845651 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin 5%
Number of subjects: 42
Study 17845651 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% modified gelatine solution
Number of subjects: 42
Study 17845651 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 (HES)
Number of subjects: 42
Study 15218813 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate treatment over 3 years
Number of subjects: 943
Study 11451751 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg daily for 6 weeks)
Number of subjects: 52
Study 11451751 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate (5-MTHF)
Number of subjects: 52
Study 11451751 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid and tetrahydrobiopterin (in vitro)
Number of subjects: 52
Study 9712496 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow supplemented with allogeneic peripheral blood cells collected by apheresis after stimulation with filgrastim
Number of subjects: 27
Study 9712496 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow alone
Number of subjects: 27
Study 2563695 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course metronidazole rectal suppositories
Number of subjects: 182
Study 2563695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 1097098 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 25
Study 1097098 — intervention group
Group type: EXPERIMENTAL
Intervention: mitomycin C
Number of subjects: 25
Study 1097098 — intervention group
Group type: COMPARATOR
Intervention: untreated historical controls
Number of subjects: 25
Study 1097098 — intervention group
Group type: EXPERIMENTAL
Intervention: catheterized patients
Number of subjects: 25
Study 30640644 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed randomized gradient-free optimization protocol
Number of subjects: 0
Study 30664487 — intervention group
Group type: EXPERIMENTAL
Intervention: eMums Plus intervention delivered via mobile phone app
Number of subjects: 160
Study 30664487 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 160
Study 28716656 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg atomoxetine
Number of subjects: 39
Study 28716656 — intervention group
Group type: EXPERIMENTAL
Intervention: 80mg atomoxetine
Number of subjects: 39
Study 28716656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 26063503 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300/75 mg regimen
Number of subjects: 72
Study 26063503 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600/150 mg regimen
Number of subjects: 72
Study 26063503 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300/75 mg regimen and 600/150 mg regimen
Number of subjects: 72
Study 23151750 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual MAP treatment goal (102‐107 mm Hg)
Number of subjects: 828
Study 23151750 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MAP treatment goal (≤92 mm Hg)
Number of subjects: 828
Study 23151750 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine in usual MAP group
Number of subjects: 828
Study 23151750 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine in low MAP group
Number of subjects: 828
Study 21722694 — intervention group
Group type: EXPERIMENTAL
Intervention: S. salivarius K12 (1 × 10(10) cfu) for 28 days
Number of subjects: 53
Study 21722694 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 28 days
Number of subjects: 53
Study 18485575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cizolirtine citrate 400 mg bid (C400)
Number of subjects: 79
Study 18485575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cizolirtine citrate 200 mg bid (C200)
Number of subjects: 79
Study 18485575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 17018196 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-systems self-management approach using a guidebook developed with patients and physicians trained in patient-centred care.
Number of subjects: 651
Study 17018196 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (control group).
Number of subjects: 651
Study 17018196 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-systems self-management approach.
Number of subjects: 651
Study 15360994 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit plus Strategic feedback (n=17)
Number of subjects: 30345
Study 15360994 — intervention group
Group type: COMPARATOR
Intervention: Audit only feedback (n=16)
Number of subjects: 30345
Study 15360994 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=19)
Number of subjects: 30345
Study 11425157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus azithromycin (Regimen A) for 12 weeks
Number of subjects: 65
Study 11425157 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole plus doxycycline (Regimen B) for 20 weeks
Number of subjects: 65
Study 9342586 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhalation at 30 degrees C
Number of subjects: 18
Study 9342586 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhalation at 40 degrees C
Number of subjects: 18
Study 9342586 — intervention group
Group type: COMPARATOR
Intervention: Nicotine inhalation at 20 degrees C
Number of subjects: 18
Study 9342586 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro results at 30 degrees C
Number of subjects: 18
Study 9342586 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro results at 40 degrees C
Number of subjects: 18
Study 8376688 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 to 20 mg/day)
Number of subjects: 4228
Study 8376688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4228
Study 3757162 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg dexamethasone i.v.
Number of subjects: 26
Study 3757162 — intervention group
Group type: COMPARATOR
Intervention: N-saline i.v. with cytotoxics
Number of subjects: 26
Study 30326480 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1034
Study 30326480 — intervention group
Group type: COMPARATOR
Intervention: Obesity, hypertension, and baseline blood pressure
Number of subjects: 1034
Study 26671818 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib with dexamethasone
Number of subjects: 929
Study 26671818 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib with dexamethasone
Number of subjects: 929
Study 24921948 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent environmental school-based intervention with 11 components
Number of subjects: 1348
Study 24921948 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 schools)
Number of subjects: 1348
Study 23009324 — intervention group
Group type: EXPERIMENTAL
Intervention: RKT‐7700
Number of subjects: 49
Study 23009324 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐80
Number of subjects: 49
Study 23009324 — intervention group
Group type: COMPARATOR
Intervention: GAT
Number of subjects: 49
Study 23009324 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal Thickness
Number of subjects: 49
Study 20363993 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 54
Study 20363993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atorvastatin therapy)
Number of subjects: 54
Study 19005437 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (700 mg of flavonoids/day for one week)
Number of subjects: 28
Study 16161727 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (8 sessions of cognitive behavioral therapy) plus antidepressant pharmacotherapy over 3 months
Number of subjects: 109
Study 16161727 — intervention group
Group type: COMPARATOR
Intervention: Assessment‐only condition
Number of subjects: 109
Study 12564947 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad cane
Number of subjects: 30
Study 12564947 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cane
Number of subjects: 30
Study 12564947 — intervention group
Group type: COMPARATOR
Intervention: No cane
Number of subjects: 30
Study 11123120 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG patch (n = 6)
Number of subjects: 12
Study 11123120 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (n = 6)
Number of subjects: 12
Study 11123120 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG patch (n = 5, at H4)
Number of subjects: 12
Study 11123120 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG patch (n = 5, at H23)
Number of subjects: 12
Study 11123120 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG patch (n = 5)
Number of subjects: 12
Study 9743404 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O (50%)
Number of subjects: 13
Study 7841703 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin intranasal spray (group A)
Number of subjects: 40
Study 7841703 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin depot im every 28 days (group B)
Number of subjects: 40
Study 7841703 — intervention group
Group type: COMPARATOR
Intervention: Untreated (group C)
Number of subjects: 40
Study 3234301 — intervention group
Group type: EXPERIMENTAL
Intervention: Al-Mg-silicate preparation (MegalacR) administered 45 min after the meal
Number of subjects: 13
Study 3234301 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 subjects)
Number of subjects: 13
Study 3234301 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PI without antacid
Number of subjects: 13
Study 31783722 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of social workers (SW) and community health workers (CHW) in primary care practices
Number of subjects: 341
Study 31288740 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 46
Study 31288740 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anaesthesia
Number of subjects: 46
Study 28077858 — intervention group
Group type: COMPARATOR
Intervention: Usual Control (UC)
Number of subjects: 2550
Study 28077858 — intervention group
Group type: COMPARATOR
Intervention: Tight Control (TC)
Number of subjects: 2550
Study 28077858 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Control (UC) and Tight Control (TC) combined
Number of subjects: 2550
Study 25924691 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral morphine
Number of subjects: 20
Study 25924691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23608758 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportal (TP) technique
Number of subjects: 76
Study 23608758 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside-in (OI) technique
Number of subjects: 76
Study 22065184 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular warm-up
Number of subjects: 1492
Study 19405039 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 90
Study 19405039 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 90
Study 17118827 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (ventilated with >96% oxygen before cardiopulmonary bypass)
Number of subjects: 22
Study 17118827 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care without hyperoxia)
Number of subjects: 22
Study 15504996 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin (Exubera) plus bedtime Ultralente
Number of subjects: 335
Study 15504996 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin regimen (two to three injections of regular and NPH insulin)
Number of subjects: 335
Study 15504996 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin (Exubera)
Number of subjects: 335
Study 11139801 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glycoprotein IIb/IIIa antagonists
Number of subjects: 0
Study 11139801 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glycoprotein IIb/IIIa antagonists
Number of subjects: 0
Study 9226607 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic fatigue syndrome patients without psychiatric disorder
Number of subjects: 69
Study 9226607 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic fatigue syndrome patients with psychiatric disorder
Number of subjects: 69
Study 9226607 — intervention group
Group type: COMPARATOR
Intervention: Psychiatric outpatients with chronic depressive disorders
Number of subjects: 69
Study 9226607 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 69
Study 8620374 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching gel (2 hours exposure)
Number of subjects: 0
Study 8620374 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching gel (7 hours exposure)
Number of subjects: 0
Study 30417697 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 6-week postoperative rehabilitation
Number of subjects: 0
Study 30417697 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited one-session postoperative rehabilitation
Number of subjects: 0
Study 30417697 — intervention group
Group type: COMPARATOR
Intervention: No postoperative rehabilitation
Number of subjects: 0
Study 30417697 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy
Number of subjects: 0
Study 30417697 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited therapy
Number of subjects: 0
Study 30417697 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 0
Study 30399122 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 8 mg
Number of subjects: 199
Study 30399122 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 199
Study 30399122 — intervention group
Group type: COMPARATOR
Intervention: Naloxone and Saline placebo (combined)
Number of subjects: 199
Study 26864140 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS plus CGT
Number of subjects: 22
Study 26864140 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS plus CGT
Number of subjects: 22
Study 25591446 — intervention group
Group type: EXPERIMENTAL
Intervention: Lessons on healthy food and changes to school vending machines (introduction of lower-calorie foods, food labelling, price reductions)
Number of subjects: 614
Study 25591446 — intervention group
Group type: EXPERIMENTAL
Intervention: Lessons on healthy food and changes to school vending machines
Number of subjects: 614
Study 25591446 — intervention group
Group type: COMPARATOR
Intervention: Control group ('care as usual')
Number of subjects: 614
Study 23334070 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg ponezumab
Number of subjects: 36
Study 23334070 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg ponezumab
Number of subjects: 36
Study 23334070 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg ponezumab
Number of subjects: 36
Study 23334070 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg ponezumab
Number of subjects: 36
Study 23334070 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg ponezumab
Number of subjects: 36
Study 23334070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 22334928 — intervention group
Group type: EXPERIMENTAL
Intervention: sinuforte (1.3 mg per procedure, once daily for 7 days)
Number of subjects: 30
Study 18668648 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 70
Study 18668648 — intervention group
Group type: COMPARATOR
Intervention: TIVA with propofol-remifentanil
Number of subjects: 70
Study 16449100 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 13
Study 16449100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 12642739 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily for 1 week, azithromycin 500 mg/d for 3 days, amoxicillin 1 g twice daily for 1 week (OAzAm group, n = 80)
Number of subjects: 160
Study 12642739 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg twice daily for 1 week, azithromycin 500 mg/d for 3 days, tinidazole 500 mg twice daily for 3 days (OAzT group, n = 80)
Number of subjects: 160
Study 10699899 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg intravenous infusion every 3-4 weeks)
Number of subjects: 751
Study 9524466 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride (AmF) solution containing 1% fluoride, biannual applications for 5 years
Number of subjects: 284
Study 9524466 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution, biannual applications for 5 years
Number of subjects: 284
Study 9524466 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride (AmF) solution containing 1% fluoride
Number of subjects: 284
Study 9524466 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 284
Study 8105512 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg i.v. bolus)
Number of subjects: 14
Study 8105512 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (7 micrograms/kg i.m.)
Number of subjects: 14
Study 8105512 — intervention group
Group type: COMPARATOR
Intervention: Saline (control for famotidine)
Number of subjects: 14
Study 8105512 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (without hG infusion)
Number of subjects: 14
Study 3513684 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 181
Study 3513684 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 181
Study 3513684 — intervention group
Group type: COMPARATOR
Intervention: Hormone withdrawal after tamoxifen
Number of subjects: 181
Study 31747012 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized regenerated cellulose (ORC)
Number of subjects: 108
Study 31747012 — intervention group
Group type: COMPARATOR
Intervention: Non-oxidized regenerated cellulose (non-ORC)
Number of subjects: 108
Study 28691598 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (30 min twice a week)
Number of subjects: 116
Study 28691598 — intervention group
Group type: COMPARATOR
Intervention: Reference group (lectures in health promotion)
Number of subjects: 116
Study 27247226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 60
Study 24051659 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg · d(‐1), n = 8 subjects)
Number of subjects: 12
Study 24051659 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 4 subjects)
Number of subjects: 12
Study 23328294 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib plus local chemotherapeutic perfusion of cisplatin 40 mg weekly for 2 weeks
Number of subjects: 30
Study 23328294 — intervention group
Group type: COMPARATOR
Intervention: sorafenib alone
Number of subjects: 30
Study 23328294 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib plus local chemotherapy
Number of subjects: 30
Study 19849696 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06% retinyl retinoate applied twice daily for 12 weeks
Number of subjects: 46
Study 19849696 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06% retinyl retinoate applied twice daily for 8 weeks
Number of subjects: 46
Study 19849696 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied for 12 weeks
Number of subjects: 46
Study 19849696 — intervention group
Group type: COMPARATOR
Intervention: 0.075% retinol applied for 8 weeks
Number of subjects: 46
Study 17855671 — intervention group
Group type: EXPERIMENTAL
Intervention: Idraparinux (2.5 mg once-weekly for 6 months)
Number of subjects: 1215
Study 17855671 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 6 months)
Number of subjects: 1215
Study 17855671 — intervention group
Group type: EXPERIMENTAL
Intervention: Idraparinux (6 additional months)
Number of subjects: 1215
Study 17855671 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonist (initial treatment)
Number of subjects: 1215
Study 15559355 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation (MEA)
Number of subjects: 322
Study 15559355 — intervention group
Group type: COMPARATOR
Intervention: Rollerball electroablation (REA)
Number of subjects: 322
Study 15559355 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation (MEA) in patients with myomas
Number of subjects: 322
Study 15559355 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation (MEA) in patients with BMI ≥ 30 kg/m2
Number of subjects: 322
Study 15559355 — intervention group
Group type: COMPARATOR
Intervention: Rollerball electroablation (REA) in patients with BMI ≥ 30 kg/m2
Number of subjects: 322
Study 11422966 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical artery Doppler velocimetry in well-defined studies
Number of subjects: 13
Study 11422966 — intervention group
Group type: COMPARATOR
Intervention: Control group (not using Doppler velocimetry)
Number of subjects: 13